The Pharma Letter M&A roundup - March 2023

4 April 2023

The long-rumored acquisition of US biotech Seagen was finally announced in March, albeit it was not long-time suitor Merck & Co (NYSE: MRK) behind the deal, but rather fellow US pharma giant Pfizer (NYSE: PFE).

With a value of $43 billion, the acquisition is likely to the biggest buy of the year and looks a good use of some of Pfizer's profits from selling COVID-19 vaccines and therapeutics over the past few years.

French drugmaker Sanofi (Euronext: SAN) also announced a multi-billion dollar transaction during March, with its $2.9 billion buy of Provention Bio, as did German life science group Sartorius (SRT: ETR), which is forking out $2.6 billion to acquire France-based Polyplus.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK